Treatment of cardiopulmonary disorders

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12138256
APP PUB NO 20240148715A1
SERIAL NO

18506944

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 μg, preferably 480 to 2000 μg of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably in form of monohydrate I of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid in form of mono hydrate (II) of formula (I-M-II), is administered to a patient in need thereof once or twice daily for a period of at least two consecutive days, preferably at least 2 to 7 consecutive days, preferably for a period of at least 14 consecutive days, in particular from after onset of treatment for the whole course of the disease, wherein the inhalative dosage form preferably comprises the combination of the active ingredient and a pharmaceutically suitable excipient or carrier, while preferably the active ingredient and a pharmaceutically suitable excipient are filled in a hard capsule.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MELBOURN SCIENTIFIC LIMITEDMELBOURN SCIENTIFIC LIMITED SAXON WAY MELBOURN HERTFORDSHIRE ROYSTON SG8 6DN

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Becker, Guido Krefeld, DE 17 472
Becker-Pelster, Eva Maria Wuppertal, DE 19 55
Bothe, Clemens Leverkusen, DE 7 5
Dietz, Lisa Wuppertal, DE 38 95
Egger, Julian Remscheid, DE 6 2
Faber, Helene Dormagen, DE 4 1
Fey, Peter Wuppertal, DE 90 959
Hahn, Michael Langenfeld, DE 178 1373
Jung, David Wittenberg, DE 28 43
Keil, Birgit Dusseldorf, DE 31 108
Lang, Dieter Velbert, DE 137 2748
Mundry, Tobias Berlin, DE 2 0
Nagelschmitz, Johannes Wuppertal, DE 2 0
Olenik, Britta Bottrop, DE 41 52
Parry, Mark Essex, GB 8 97
Rösler, Bernd Wuppertal, DE 3 0
Richter, Annett Berlin, DE 10 18
Saleh, Soundos Wuppertal, DE 2 0
Schirmer, Heiko Solingen, DE 59 134
Terebesi, Ildiko Berlin, DE 14 44
Tinel, Hanna Wuppertal, DE 52 196
Vitre, Cecile Cambridgeshire, GB 2 0
Ward, David Cambridgeshire, GB 199 4886
Weimann, Gerrit Bergisch-Gladbach, DE 8 17

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 12, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 May 12, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 12, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00